Answers are grounded in this paper and cite their sources.
Rare disease clinical trials face unique challenges, resulting in low enrollment and limited retention. Digital health technologies (DHTs), when applied through a patient-centric lens, offer promising solutions to these challenges by enhancing data collection efficiency, improving patient engagement, and supporting long-term health care. This study investigates DHT application in clinical studies across the ten most-studied rare diseases and was registered with PROSPERO (registration number: CRD420251088025). Up to June 26 2024, a total of 262 studies were identified through ClinicalTrials.gov, the International Clinical Trials Registry Platform, Cochrane Central Register of Controlled Trials, PubMed, and Web of Science. DHT applications were classified into patient recruitment, digital treatment, data monitoring and collection, outcome assessment, remote follow-up, and long-term care management based on scenarios and functionalities. Among all DHT applications, data monitoring and collection was the most prevalent (31.3%), serving primarily to enable continuous tracking of physiological parameters relevant to specific rare disease conditions. Digital treatment is featured in 57 studies (21.8%), most commonly as digital physiotherapy. A notable increase in DHT adoption is observed from 2017–2020 to 2021–2024 across nearly all ten diseases. Between 2021 and 2024, cystic fibrosis shows the highest proportion of DHT-enabled trials relative to all studies conducted for that disease (29.7%). Our findings reveal a growing trend toward digital integration in rare disease trials to support decentralized, scalable, and patient-centered research models. We propose a “4A” conceptual framework—Accessibility, Agility, Awareness, and Adaptability to accelerate therapeutic development and expand access to care for these underserved rare disease populations. Mao et al. systematically evaluates the integration of digital health technologies (DHT) in 262 clinical trials across ten rare diseases. Results reveal that DHTs enable remote monitoring, digital interventions and patient support, enhancing trial inclusivity, authors also propose a “4A” framework for DHT implementation. Hundreds of millions of people around the world live with rare diseases, but most of these conditions still don’t have effective treatments. Clinical trials are vital for new therapies, but rare disease trials are especially challenging due to small, dispersed patient populations and difficulties with long-term participation. This study looked at how digital health tools—like wearable devices, mobile apps, and healthcare platforms—are being used to improve rare disease clinical trials. We analysed 262 trials across ten rare diseases and found that digital health technologies were increasingly used for remote monitoring, digital treatment, and long-term care. By making it easier for patients to participate in trials—no matter where they live—digital technologies can help speed up the development of much-needed treatments and help make research more inclusive and equitable by reaching patients who would otherwise be left out.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: